Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation

Abstract Blinatumomab, a CD19/CD3 bispecific T-cell engager, is frequently used for B-cell acute lymphoblastic leukemia (B-ALL) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although its efficacy in achieving measurable residual disease negativity is well established, its...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Hai-Lu Sun, Zhi-Fan Zhao, Xian-Ying Yin, Meng Lv, Ling Ma, Fang-Fang Wei, Xiao-Su Zhao, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Xu-Ying Pei
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Springer 2026-01-01
Serie:	Annals of Hematology
Ämnen:	Blinatumomab Acute lymphoblastic leukemia Allogeneic stem cell transplantation EBV viremia
Länkar:	https://doi.org/10.1007/s00277-026-06738-2
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!